HC Wainwright reissued their neutral rating on shares of HilleVax (NASDAQ:HLVX – Free Report) in a report issued on Monday morning, Benzinga reports. The brokerage currently has a $2.00 price target on the stock.
HLVX has been the topic of a number of other reports. Stifel Nicolaus lowered shares of HilleVax from a buy rating to a hold rating and reduced their target price for the company from $34.00 to $3.00 in a report on Tuesday, July 9th. SVB Leerink downgraded shares of HilleVax from an outperform rating to a market perform rating and reduced their price objective for the company from $28.00 to $2.00 in a research note on Tuesday, July 9th. Guggenheim cut shares of HilleVax from a buy rating to a neutral rating in a research note on Monday, July 8th. Leerink Partnrs lowered HilleVax from a strong-buy rating to a hold rating in a research note on Tuesday, July 9th. Finally, JPMorgan Chase & Co. reaffirmed a neutral rating and issued a $5.00 price objective (down previously from $24.00) on shares of HilleVax in a research report on Monday, July 8th. Six analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has a consensus rating of Hold and an average target price of $9.20.
Check Out Our Latest Report on HilleVax
HilleVax Trading Down 1.8 %
HilleVax (NASDAQ:HLVX – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). Sell-side analysts anticipate that HilleVax will post -2.58 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, Director Aditya Kohli sold 6,000 shares of the business’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $14.73, for a total transaction of $88,380.00. Following the completion of the sale, the director now directly owns 764,878 shares of the company’s stock, valued at approximately $11,266,652.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 71.10% of the stock is currently owned by insiders.
Institutional Trading of HilleVax
A number of institutional investors have recently modified their holdings of the company. EntryPoint Capital LLC acquired a new stake in HilleVax during the 1st quarter worth approximately $80,000. SG Americas Securities LLC acquired a new stake in shares of HilleVax in the fourth quarter worth $139,000. Tidal Investments LLC acquired a new stake in shares of HilleVax in the first quarter worth $207,000. abrdn plc purchased a new position in shares of HilleVax in the 4th quarter valued at $433,000. Finally, Swiss National Bank lifted its holdings in shares of HilleVax by 22.4% during the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after acquiring an additional 7,000 shares in the last quarter. Hedge funds and other institutional investors own 86.42% of the company’s stock.
HilleVax Company Profile
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
See Also
- Five stocks we like better than HilleVax
- Retail Stocks Investing, Explained
- Brinker International’s Price Dip is an Appetizing Entry Point
- How to Effectively Use the MarketBeat Ratings Screener
- 3 Stocks That Could Beat the September Blues
- How to Invest in the Best Canadian StocksÂ
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.